[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Istanbul Training and Research Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":253},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,78,108,143,171,199,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645016","ai-based-risk-classification-and-histopathological-subtype-prediction-of-basal-cell-carcinoma-using-dermoscopic-images-100645016",false,"NCT07677124","AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images","Risk Classification and Prediction of Histopathological Subtypes in Basal Cell Carcinoma Using a CNN-Based Artificial Intelligence Model on Dermoscopic Images","BCC-AI","Inclusion Criteria:\n\n* Patients with histopathologically confirmed basal cell carcinoma.\n* Cases with a specified histopathological subtype.\n* Availability of dermoscopic images with sufficient image quality and resolution for artificial intelligence analysis.\n\nExclusion Criteria:\n\n* Cases without histopathological confirmation of basal cell carcinoma.\n* Cases with unspecified histopathological subtype.\n* Images with insufficient quality or resolution for artificial intelligence analysis.\n* Cases without available dermoscopic images.","ALL","0 Years","100 Years",{"count":21,"type":22},2500,"ESTIMATED","OBSERVATIONAL","This retrospective observational study aims to develop and evaluate a convolutional neural network (CNN)-based artificial intelligence model for risk classification and histopathological subtype prediction of basal cell carcinoma (BCC) using clinical and dermoscopic images. Histopathologically confirmed BCC cases from a dermatology archive will be included. The primary objective is to assess the diagnostic performance of the CNN model in classifying BCC as low-risk or high-risk. Secondary objectives include predicting histopathological subtypes and comparing the model's performance with that of dermatology physicians. Histopathological diagnosis will serve as the reference standard. All archived data will be anonymized before analysis.",[26],"Basal Cell Carcinoma",[26,28,29,30,31,32,33],"Artificial Intelligence","Convolutional Neural Network","Dermoscopy","Skin Cancer","Histopathological Subtypes","Risk Classification","RECRUITING","2026-06-29",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2026-05-22",{"date":42,"type":22},"2027-05-22",{"name":44,"class":45},"Istanbul Training and Research Hospital","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100618761","the-effectiveness-of-low-level-laser-therapy-in-the-treatment-of-meralgia-paresthetica-100618761","NCT07335822","The Effectiveness of Low-Level Laser Therapy in the Treatment of Meralgia Paresthetica","Inclusion Criteria: Patients aged 18 to 70 with neuropathic complaints in the anterolateral thigh, whose diagnosis has been confirmed by sensory conduction studies of the lateral femoral cutaneous nerve.\n\nExclusion Criteria: - Patients with diabetes mellitus\n\n* Patients with polyneuropathy\n* Patients with radicular pain\n* Patients receiving treatment for neuropathic pain\n* Patients who have received an injection to the lateral femoral cutaneous nerve within the last three months\n* Patients who have undergone physical therapy modalities for a diagnosis of meralgia paresthetica within the last three months\n* Patients with a history of pelvic surgery\n* Patients diagnosed with rheumatologic diseases\n* Pregnant women\n* Patients with active skin infections\n* Malignancy\n* Fibromyalgia","18 Years","70 Years",{"count":56,"type":22},44,"INTERVENTIONAL",[59],"NA","Patients diagnosed with meralgia paresthetica via electromyography (EMG), who present with neuropathic complaints on the lateral thigh to the Physical Medicine and Rehabilitation outpatient clinics of our hospital, will be included in the study after reviewing exclusion criteria. Patients will be randomized into two equal groups using a sealed-envelope system. The treatment group will receive low-level laser therapy (LLLT) combined with simultaneous transcutaneous electrical nerve stimulation (TENS), while the control group will receive placebo laser therapy combined with simultaneous TENS.\n\nAn LED gallium-aluminum-arsenide (Ga-Al-As) diode laser device with a power of 1.6 W and a wavelength of 808 nm will be used in the study. The treatment will consist of 10 sessions, applied over two weeks, five days per week.\n\nDemographic data (age, gender, body mass index, and occupation) of all patients included in the study will be recorded. Pain and functional impairment will be evaluated using the VAS, SF-36, PSQI, and S-LANSS scales for all patients. VAS, SF-36, PSQI, and S-LANSS scores will be assessed at the end of the treatment and on the 30th day after treatment completion (6th-week after baseline). The effectiveness of low-level laser therapy will be investigated using statistical data analysis methods.\n\nLow-level laser therapy will be applied perpendicularly, consistent with the lateral femoral cutaneous nerve projection, delivering a total of 4 J of energy over 12 minutes. TENS electrodes will be placed on the painful anterolateral thigh region in both groups. The stimulation pulse frequency will be set to 100 Hz, and the pulse width will be set to 100 ms. In the control group, sham laser will be applied using the same device and in the same manner; however, no laser beam will be emitted to the designated areas.",[62,63],"Meralgia Paresthetica","Lateral Femoral Cutaneous Nerve Entrapment",[62,65,66,67,68],"Lateral Femoral Cutaneous Nerve","Entrapment neuropathy","Low-Level Laser Therapy","thigh pain","2026-03-04",{"date":71,"type":38},"2026-03-05",{"date":73,"type":22},"2026-03-02",{"date":75,"type":22},"2026-06-05",{"name":44,"class":45},2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":46},"100622540","correlation-of-dermoscopic-findings-with-histopathological-features-and-invasion-depth-in-cutaneous-squamous-cell-carcinoma-100622540","NCT07384949","Correlation of Dermoscopic Findings With Histopathological Features and Invasion Depth in Cutaneous Squamous Cell Carcinoma","Correlation of Invasion Depth and Histopathological Features With Dermoscopic Findings in Cutaneous Squamous Cell Carcinoma","SCC-DERM","Inclusion Criteria:Age between 18 and 100 years at the time of diagnosis\n\nHistopathologically confirmed cutaneous squamous cell carcinoma\n\nLesions that underwent total surgical excision\n\nHistopathology reports including both tumor differentiation grade and invasion depth\n\nAvailability of dermoscopic images obtained prior to excision\n\nDermoscopic images of sufficient quality for evaluation and image analysis -\n\nExclusion Criteria:\n\nLesions that received any prior treatment, including radiotherapy, chemotherapy, cryotherapy, or other destructive or topical treatments before excision\n\nIncomplete clinical, dermoscopic, or histopathological data\n\nPoor-quality dermoscopic images not suitable for reliable evaluation or segmentation\n\n\\-",{"count":87,"type":22},238,"This is a retrospective study including patients diagnosed with cutaneous squamous cell carcinoma between 2016 and 2025. Demographic, clinical, histopathological, and dermoscopic data were obtained from hospital records. Dermoscopic images taken with the FotoFinder dermoscope were independently evaluated by two dermatologists in a blinded manner. In addition, images were labeled using computer software and analyzed to measure the proportion of specific dermoscopic structures within the total lesion area. These quantitative data were used to examine the relationship between dermoscopic features and histopathological findings.",[90],"Cutaneous Squamous Cell Cancer",[92,93,94,95,96,97,98],"dermoscopy","Dermoscopic features","Histopathology correlation","Tumor invasion depth","Skin cancer imaging","Computer-assisted image analysis","Squamous cell carcinoma","NOT_YET_RECRUITING","2026-01-27",{"date":102,"type":38},"2026-02-03",{"date":104,"type":22},"2026-02-01",{"date":106,"type":22},"2026-06",{"name":44,"class":45},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":53,"maxAge":116,"enrollmentInfo":117,"targetDuration":119,"studyType":23,"phases":4,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":46},"100620866","nailfold-capillaroscopy-and-endothelial-biomarkers-in-healthcare-workers-exposed-to-chronic-low-dose-ionizing-radiation-100620866","NCT07363187","Nailfold Capillaroscopy and Endothelial Biomarkers in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation","Evaluation of Microvascular Changes by Nailfold Capillaroscopy and Serum ADMA, Von Willebrand Factor, Hs-CRP, and D-dimer Levels in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation","Inclusion Criteria:\n\n* Healthcare workers aged between 18 and 60 years.\n* For the control group: Employment in a healthcare institution with either occupational exposure to low-dose ionizing radiation or no occupational radiation exposure.\n* For the exposed group: chronic occupational exposure to ionizing radiation for at least 3 years.\n* Willingness and ability to provide written informed consent.\n* Ability to comply with study procedures, including nailfold capillaroscopy and blood sample collection.\n\nExclusion Criteria:\n\n* History of cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.\n* Presence of systemic diseases that may affect microvascular structure or endothelial function, including diabetes mellitus, uncontrolled hypertension, dyslipidemia, or chronic kidney disease.\n* Known autoimmune, connective tissue, or systemic inflammatory diseases (e.g., systemic sclerosis, lupus erythematosus, vasculitis).\n* Active infection or acute inflammatory condition at the time of enrollment.\n* Use of systemic medications that may affect endothelial function or microcirculation within the past 4 weeks, including vasodilators, antihypertensive agents, statins, antiplatelet or anticoagulant drugs.\n* Current smoking or history of smoking within the past 6 months.\n* Pregnancy or breastfeeding.\n* History of malignancy or current cancer treatment.\n* Previous finger trauma, surgery, or local conditions affecting the nailfold area that may interfere with capillaroscopic evaluation.",true,"60 Years",{"count":118,"type":22},90,"1 Day","Chronic occupational exposure to low-dose ionizing radiation may lead to subclinical endothelial dysfunction and early microvascular alterations in healthcare workers. Nailfold capillaroscopy is a non-invasive method that allows direct visualization of microcirculatory changes. This observational study aims to evaluate microvascular alterations using nailfold capillaroscopy and to assess their association with serum endothelial and inflammatory biomarkers, including asymmetric dimethylarginine (ADMA), von Willebrand factor (vWF), high-sensitivity C-reactive protein (hs-CRP), and D-dimer levels. Healthcare workers with chronic low-dose radiation exposure will be compared with non-exposed controls. The study seeks to improve understanding of early vascular effects of occupational radiation exposure.",[122,123,124],"Microvascular Dysfunction","Endothelial Dysfunction","Occupational Radiation Exposure",[126,127,128,129,130,131,132,133,134,135],"Nailfold capillaroscopy","Microvascular changes","Low-dose ionizing radiation","Occupational radiation exposure","Healthcare workers","Endothelial dysfunction","Inflammation biomarkers","D-dimer","High-sensitivity C-reactive protein","Asymmetric dimethylarginine","2026-01-22",{"date":138,"type":38},"2026-01-26",{"date":104,"type":22},{"date":141,"type":22},"2026-05-01",{"name":44,"class":45},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":57,"phases":153,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":46},"100604529","effects-of-close-follow-up-on-patients-with-low-back-pain-100604529","NCT07150702","Effects of Close Follow-up on Patients With Low Back Pain","The Effect of Close Follow-up by a Physician in Addition to a Conventional Physical Therapy Program in Patients With Low Back Pain","Inclusion Criteria:\n\n* Patients aged 18-65 with subacute or chronic mechanical back pain and considered appropriate for a physical therapy program.\n\nExclusion Criteria:\n\n* Patients describing inflammatory back pain\n* Spondyloarthropathies and other rheumatological diseases\n* History of spinal surgery\n* Patients with sensory disturbances and psychiatric diagnoses\n* Fibromyalgia\n* Patients with malignancies\n* Patients with active infectious findings\n* Patients with a history of radiotherapy","65 Years",{"count":152,"type":22},74,[59],"This study will include patients aged 18-65 with subacute or chronic mechanical low back pain who apply to the Physical Medicine and Rehabilitation Clinic. The age, gender, body mass index, duration of low back pain, smoking status, and educational status of the patients included in the study will be recorded. Patients will be randomized into two groups: the study group and the control group. First, the psychosocial risk status of patients in both groups will be determined using the STarT Back Screening Tool. Then, patients in the control group will undergo a conventional physical therapy program that includes hot packs, transcutaneous electrical nerve stimulation, ultrasound, and core stabilization exercises. Patients in the study group will undergo daily close follow-up physician-patient meetings during the sessions, in addition to the conventional physical therapy program applied to the control group. Clinical assessments will be performed using the Visual Analogue Scale (VAS), Tampa Scale of Kinesiophobia, Pain Catastrophizing Scale, Beck's Depression Scale, Roland-Morris Disability Questionnaire, and Leeds Assessment of Neuropathic Symptoms and Signs. Clinical evaluations will be conducted at baseline, on Day 5 post-treatment, and at 1 month post-treatment.",[156,157],"Low Back Pain","Low Back Pain, Mechanical",[159,160,161,162],"low back pain","physical therapy","mechanical low back pain","pain management","2025-09-13",{"date":165,"type":38},"2025-09-16",{"date":167,"type":38},"2025-09-01",{"date":169,"type":22},"2025-12-10",{"name":44,"class":45},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":178,"minAge":53,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":57,"phases":181,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":46},"100593174","immun-checkpoint-washout-in-patients-with-invasive-ductal-breast-cancer-100593174","NCT07003009","Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer","Detection of Lymph Node Positivity in Patients With Invasive Ductal Breast Cancer Using Immun Checkpoint Washout","Inclusion Criteria:\n\n* Histopathologically proven invasive ductal carcinoma\n* Patients who will have neoadjuvant therapy\n\nExclusion Criteria:\n\n* The fine-needle aspiration biopsy (FNAB) result of the suspected metastatic lymph node is negative.\n* The FNAB result of the presumed healthy lymph node is malignant.\n* They refuse to participate in the study.\n* They have another primary malignancy.\n* They are pregnant.\n* They have a history of immunodeficiency.","FEMALE",{"count":180,"type":22},30,[59],"Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and in symptomatic cases, up to 60% of cases. The clinical detection accuracy of axillary lymph node metastases is only 33%. Accurate staging of lymph nodes in breast cancer patients is crucial for both prognosis and treatment. Ultrasonography is much more sensitive than physical examination alone for determining axillary lymph node involvement in breast cancer staging. Fine needle aspiration biopsy or core biopsy is diagnostic in lymph nodes that cannot be clarified solely by ultrasonography or are suspicious. Although biopsy sampling yields high diagnostic rates, it requires an experienced pathologist and sometimes takes weeks to yield results. Therefore, there is a need for faster and less costly diagnostic methods for diagnosing axillary metastases. Among thyroid cancers, papillary thyroid carcinomas, a malignancy in which the lymph node washout method is used to determine lymph node metastasis, are the most common. In papillary thyroid cancer patients, washout sampling of neck lymph nodes by fine needle aspiration, searching for thyroglobulin, a protein normally found in thyroid tissue, is considered one of the most valid methods for detecting lymph node metastasis in this cancer. In recent years, immune checkpoint molecules associated with cancer have been widely used as biomarkers and agents in both diagnosis and treatment for cancer patients. There are numerous publications in the literature regarding the expression of immune checkpoint molecules such as Programmed cell death protein 1 (PD-1), Programmed death ligand 1 (PD-L1), and The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) on the cell surface of breast cancer patients. Although the natural soluble forms of receptors and ligands of immune checkpoint molecules exist and they are important components of immune regulation, their exact mechanisms of action have not yet been determined. There are five studies in the literature evaluating the status of soluble immune checkpoint molecules in breast cancer patients, with one being a review article. It is highly likely that immune checkpoint molecules found on both the cell surface and soluble in blood and body fluids are also present in tumor metastatic regions. There is no study using these immunological biomarkers to determine metastasis in invasive ductal carcinoma patients with metastatic axillary lymph nodes ın the literature. In this study, the investigators will evaluate the soluble levels of immune checkpoint molecules in washout fluids obtained from metastatic axillary lymph nodes and benign lymph nodes in patients with invasive ductal breast carcinoma, and will assess the effectiveness of these immune checkpoint molecules and the washout method in diagnosing metastasis.",[184,185],"Breast Cancer Metastatic","Breast Carcinoma",[187,188,189,190],"Immune checkpoints","Breast Cancer","Lymph node","Washout","2025-05-31",{"date":193,"type":38},"2025-06-04",{"date":195,"type":38},"2024-01-01",{"date":197,"type":22},"2025-10-01",{"name":44,"class":45},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":178,"minAge":53,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":57,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":46},"100592838","effectvty-of-chitosan-covered-gauze-in-postpartum-hemorrhagic-obstetric-lacerations-100592838","NCT06998641","EFFECTİVİTY OF CHITOSAN COVERED GAUZE IN POSTPARTUM HEMORRHAGIC OBSTETRIC LACERATIONS","Inclusion Criteria: Patients, 18-48 years old, who gave birth in Istanbul TRH between March 2025 and March 2027 experiencing 1st and 2nd degree obstetric lacerations with postpartum hemorrhage without the need for anatomical defect repairing and without additional conditions such as uterine atony, placental rest, etc. that may affect the amount of postpartum bleeding.\n\nExclusion Criteria: Patients not fullfilling the inclusion criteria in terms of age limits, time and place of birth or ones who are experiencing 1st and 2nd degree obstetric lacerations with postpartum hemorrhage with the need for anatomical defect repairing and with additional conditions such as uterine atony, placental rest, etc. that may affect the amount of postpartum bleeding.","48 Years",{"count":207,"type":22},62,[59],"This study was planned to investigate the efficacy of different treatment methods that can be used in the treatment of hemorrhagic tears that may occur in the postpartum period. The volunteers who will participate in the study will be evaluated during the hospitalization period after delivery and at the end of the puerperium 6 weeks after delivery, in accordance with routine postpartum control examinations. In the treatment of postpartum hemorrhagic tears, the treatment options such as suturing the tears to stop bleeding or applying tampons with bleeding stopping agent (chitosan) and compression effect to the torn area will be determined completely randomly.",[211,212],"Effectiveness of Chitosan Covered Gauze to Stop Bleeding in Post-partum Tears","Comparison of the Effect of Chitosan Covered Gauze With Suturing in Terms of Hemostasis in Post-partum Haemorrhagic Tears",[214,215,216],"chitosan-covered-gauze","post-partum lacerations","obstetrical tears","2025-05-22",{"date":191,"type":38},{"date":220,"type":38},"2025-03-01",{"date":222,"type":22},"2028-12",{"name":44,"class":45},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":231,"maxAge":119,"enrollmentInfo":232,"targetDuration":4,"studyType":57,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":46},"100550444","continuous-versus-bolus-feeding-in-neonates-with-hypoxic-ischemic-encephalopathy-100550444","NCT06447155","Continuous Versus Bolus Feeding in Neonates With Hypoxic Ischemic Encephalopathy","The Impact of Continuous Versus Bolus Feeding in Neonates With Hypoxic Ischemic Encephalopathy Undergoing Therapeutic Hypothermia","Inclusion Criteria:\n\n* The neonates with evidence of encephalopathy de¬fined by seizures or abnormalities on a modified Sarnat exam were enrolled. The hypoxic-ischemic injury was defined by 1. a pH of ≤ 7.0 and\u002For 2. base deficit \\>-16 mmol\u002FL recorded in cord blood or blood gas obtained within the first hour postnatally or a pH of 7.0 - 7.15 and\u002For base deficit (-10-15.9) mmol\u002FL with the presence of an acute perinatal event (cord prolapse, placental abruption, heart rate decelerations, severe fetal bradycardia). In cases where criteria 1 or 2 are met, with the presence of seizures or a diagnosis of moderate to severe encephalopathy according to the Sarnat \\& Sarnat classification based on neurological examination were treated with TH.\n\nExclusion Criteria: Infants with congenital malformation or hereditary metabolic diseases, infants whose enteral feeding was initiated before randomization and infants without lack of parental consent were excluded. The maternal and neonatal demographic characteristics and clinical outcomes were collected from medical records.\n\n\\-","0 Days",{"count":233,"type":22},60,[59],"Therapeutic hypothermia (TH) is accepted worldwide as a standard of care for infants born at or beyond 36 weeks gestational age with moderate-to-severe hypoxic ischaemic encephalopathy (HIE).\n\nWhile central nervous system is the most affected organ system , multiorgan dysfunction including renal, pulmonary, cardiac, and\u002For gastrointestinal (GI) compromise is not infrequent. Although the process of 'cooling' itself is well defined, based on high-quality randomized controlled trials, there are few data to inform the provision of nutrition to infants with HIE during and soon after TH.However, breastfeeding plays a beneficial role in maintaining the structural and functional integrity of the gut. It may help to reduce systemic inflammatory response and positively regulates the microbiota. In many studies it is stated that enteral feeding during TH appears to be safe and feasible. There is insufficient evidence to choose the type of enteral feeding either bolus or continuous during TH.\n\nThe present study aimed to compare the impact of different types of enteral feeding in infants with HIE receiving TH.",[237,238],"Hypoxic Ischemic Encephalopathy of Newborn","Feeding Patterns",[240,241,242,243,244],"Newborn","Hypoxic ischemic encephalopathy","Enteral feeding","Bolus","Continuous","2024-06-03",{"date":247,"type":38},"2024-06-06",{"date":249,"type":22},"2024-06-15",{"date":251,"type":22},"2026-06-15",{"name":44,"class":45},""]